About this trial
This study seeks to develop an RS-ART implementation strategy by utilizing the Delphi method and interviewing experts and PWID regarding their experiences with ART. This strategy will then be pilot tested in a randomized controlled trial (Aim 3). The research will not impact the type of medication and dose prescribed, but rather, how soon providers are able to prescribe ART after diagnosis. The focus of this registration is Aim 3.
Eligibility criteria
Qualifiers
Be a PWID from the general population enrolling into ART services at one of the study's HIV clinics. PWID can include patients injecting opioids, amphetamines, or other combinations of injectable drugs. Some of these patients may be diagnosed with Opioid Use Disorder (OUD).
Provide informed consent.
HIV clinicians prescribing ART
Be the HIV clinician who prescribes ART for a PWID in one of the selected clinics.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Rapid-Start ART (RS-ART)
Treatment groups
Sponsors and collaborators
Yale University
Lead sponsor
National Institute of Mental Health (NIMH)
Collaborator
Fogarty International Center of the National Institute of Health
Collaborator